<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32799899</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>The role of TDP-43 mislocalization in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>45</StartPage><MedlinePgn>45</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">45</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-020-00397-1</ELocationID><Abstract><AbstractText>Since its discovery as a primary component in cytoplasmic aggregates in post-mortem tissue of patients with Amyotrophic Lateral Sclerosis (ALS), TAR DNA Binding Protein 43&#x2009;kDa (TDP-43) has remained a central focus to understand the disease. TDP-43 links both familial and sporadic forms of ALS as mutations are causative for disease and cytoplasmic aggregates are a hallmark of nearly all cases, regardless of TDP-43 mutational status. Research has focused on the formation and consequences of cytosolic protein aggregates as drivers of ALS pathology through both gain- and loss-of-function mechanisms. Not only does aggregation sequester the normal function of TDP-43, but these aggregates also actively block normal cellular processes inevitably leading to cellular demise in a short time span. Although there may be some benefit to therapeutically targeting TDP-43 aggregation, this step may be too late in disease development to have substantial therapeutic benefit. However, TDP-43 pathology appears to be tightly linked with its mislocalization from the nucleus to the cytoplasm, making it difficult to decouple the consequences of nuclear-to-cytoplasmic mislocalization from protein aggregation. Studies focusing on the effects of TDP-43 mislocalization have demonstrated both gain- and loss-of-function consequences including altered splicing regulation, over responsiveness to cellular stressors, increases in DNA damage, and transcriptome-wide changes. Additionally, mutations in TARDBP confer a baseline increase in cytoplasmic TDP-43 thus suggesting that small changes in the subcellular localization of TDP-43 could in fact drive early pathology. In this review, we bring forth the theme of protein mislocalization as a key mechanism underlying ALS, by highlighting the importance of maintaining subcellular proteostasis along with the gain- and loss-of-functional consequences when TDP-43 localization is dysregulated. Additional research, focusing on early events in TDP-43 pathogenesis (i.e. to the protein mislocalization stage) will provide insight into disease mechanisms, therapeutic targets, and novel biomarkers for ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suk</LastName><ForeName>Terry R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>University of Ottawa Brain and Mind Research Institute, Ottawa, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rousseaux</LastName><ForeName>Maxime W C</ForeName><Initials>MWC</Initials><Identifier Source="ORCID">0000-0002-2737-6193</Identifier><AffiliationInfo><Affiliation>University of Ottawa Brain and Mind Research Institute, Ottawa, Canada. max.rousseaux@uottawa.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada. max.rousseaux@uottawa.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Eric Poulin Center for Neuromuscular Diseases, Ottawa, Canada. max.rousseaux@uottawa.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ottawa Institute of Systems Biology, Ottawa, Canada. max.rousseaux@uottawa.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Mislocalization</Keyword><Keyword MajorTopicYN="N">Nucleocytoplasmic shuttling</Keyword><Keyword MajorTopicYN="N">Pathology</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32799899</ArticleId><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pii">10.1186/s13024-020-00397-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Prim. Nature Publishing Group. 2017;3:17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HP, Van Broeckhoven C, van der Zee J. ALS genes in the genomic era and their implications for FTD. Trends Genet. 2018;34:404&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17:94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008;7:409&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546119</ArticleId><ArticleId IdType="pubmed">18396105</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesiridis GS, Lee VMY, Trojanowski JQ. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet. 2009;18:R156&#x2013;R162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758707</ArticleId><ArticleId IdType="pubmed">19808791</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande VC, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet (London, England) 2011;377:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. Nat Publ Group. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Bosco DA, LeClerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortob&#xe1;gyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer RC, Chami AA, De Assis DR, Vourc&#x2019;h P, Andres CR, Corcia P, et al. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: A resolution in sight? Brain. 2019;142:1176&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61:427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D, et al. TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol. 2008;63:535&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747362</ArticleId><ArticleId IdType="pubmed">18288693</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Functional significance of TDP-43 mutations in disease. Adv Genet. 2015;91:1&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu ZS. Does a loss of TDP-43 function cause neurodegeneration? Mol Neurodegener. 2012;7:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3419078</ArticleId><ArticleId IdType="pubmed">22697423</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Wen N, Fan CC, Yokoyama JS, Kouri N, Ross OA, et al. Selective genetic overlap between amyotrophic lateral sclerosis and diseases of the frontotemporal dementia Spectrum. JAMA Neurol. 2018;75(7):860&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6043387</ArticleId><ArticleId IdType="pubmed">29630712</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Bonvicini C, Alberici A, Buratti E, Agosti C, Archetti S, et al. Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Hum Mutat. 2009;30:E974&#x2013;E983.</Citation><ArticleIdList><ArticleId IdType="pubmed">19655382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong LK, Neumann M, Sampathu DM, Lee VMY, Trojanowski JQ. TDP-43 proteinopathy: The neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol. 2007;114:63&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">17492294</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HY, Wang IF, Bose J, Shen CKJ. Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics. 2004;83:130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">14667816</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreyfuss G, Matunis MJ, Pinol-Roma S, Burd CG. hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem. 1993;62:289&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">8352591</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem. 2001;276:36337&#x2013;36343.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Brindisi A, Pagani F, Baralle FE. Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance [2] Am J Hum Genet. 2004;74:1322&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182100</ArticleId><ArticleId IdType="pubmed">15195661</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo PH, Chiang CH, Wang YT, Doudeva LG, Yuan HS. The crystal structure of TDP-43 RRM1-DNA complex reveals the specific recognition for UG- and TG-rich nucleic acids. Nucleic Acids Res. 2014:4712&#x2013;22 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985631/. Cited 2020 Jun 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3985631</ArticleId><ArticleId IdType="pubmed">24464995</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Zago P, D&#x2019;Ambrogio A, Xu Y-FFY-F, Petrucelli L, Buratti E, et al. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 2008;121:3778&#x2013;3785.</Citation><ArticleIdList><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wang L, Lu J, Siedlak SL, Fujioka H, Liang J, et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat Med. 2016;22:869&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4974139</ArticleId><ArticleId IdType="pubmed">27348499</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VMY. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem. 2008;283:13302&#x2013;13309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Avenda&#xf1;o-V&#xe1;zquez SE, Dhir A, Bembich S, Buratti E, Proudfoot N, Baralle FE. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev. 2012;26:1679&#x2013;1684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418585</ArticleId><ArticleId IdType="pubmed">22855830</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Kim E, Duffy A, Adalbert R, Phillips BU, Peters OM, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21:1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">29872124</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugai A, Kato T, Koyama A, Koike Y, Konno T, Ishihara T, et al. Non-genetically modified models exhibit TARDBP mRNA increase due to perturbed TDP-43 autoregulation. Neurobiol Dis. 2019;130:104534.</Citation><ArticleIdList><ArticleId IdType="pubmed">31310801</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Wang H, Qiao T, Yang B, Aliaga L, Qiu L, et al. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2014;111:E1121&#x2013;E1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3970502</ArticleId><ArticleId IdType="pubmed">24616503</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid B, Hruscha A, Hogl S, Banzhaf-Strathmann J, Strecker K, Van Der Zee J, et al. Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. Proc Natl Acad Sci U S A. 2013;110:4986&#x2013;4991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3612625</ArticleId><ArticleId IdType="pubmed">23457265</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, Katsuno M, Niwa JI, Takagi S, Ishigaki S, Ikenaka K, et al. Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain. 2013;136:1371&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pubmed">23449777</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu LS, Cheng WC, Shen CKJ. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. J Biol Chem. 2012;287:27335&#x2013;27344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431639</ArticleId><ArticleId IdType="pubmed">22718760</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2010;107:3858&#x2013;3863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog JJ, Deshpande M, Shapiro L, Rodal AA, Paradis S. TDP-43 misexpression causes defects in dendritic growth. Sci Rep. 2017;7:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5688077</ArticleId><ArticleId IdType="pubmed">29142232</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2009;106:18809&#x2013;18814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y-FF, Gendron TF, Zhang Y-JJ, Lin W-LL, D&#x2019;Alton S, Sheng H, et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci. 2010;30:10851&#x2013;10859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiesel FC, Schurr C, Weber SS, Kahle PJ. TDP-43 knockdown impairs neurite outgrowth dependent on its target histone deacetylase 6. Mol Neurodegener. 2011;6:64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170629</ArticleId><ArticleId IdType="pubmed">21878116</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, Katsuno M, Niwa JI, Yamada SI, Sone J, Waza M, et al. TDP-43 depletion induces neuronal cell damage through dysregulation of rho family GTPases. J Biol Chem. 2009;284:22059&#x2013;22066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755930</ArticleId><ArticleId IdType="pubmed">19535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, Bourgouin P, et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet. 2009;19:671&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">19959528</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanden Broeck L, Naval-S&#xe1;nchez M, Adachi Y, Diaper D, Dourlen P, Chapuis J, et al. TDP-43 loss-of-function causes neuronal loss due to defective steroid receptor-mediated gene program switching in Drosophila. Cell Rep. 2013;3:160&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">23333275</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaper DC, Adachi Y, Sutcliffe B, Humphrey DM, Elliott CJH, Stepto A, et al. Loss and gain of Drosophila TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes. Hum Mol Genet. 2013;22:1539&#x2013;1557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605831</ArticleId><ArticleId IdType="pubmed">23307927</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer BC, Schuck T, Wheeler JM, Robinson LC, Trojanowski JQ, Lee VMY, et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 2010;119:409&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880609</ArticleId><ArticleId IdType="pubmed">20198480</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton CF, Good SK, Atkin S, Dewey CM, Mayer P, Herz J, et al. TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem. 2010;285:6826&#x2013;6834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825476</ArticleId><ArticleId IdType="pubmed">20040602</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu LS, Cheng W, Hou SC, Yan YT, Jiang ST, Shen CKJ. TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis. Genesis. 2010;48:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">20014337</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinarbasi ES, Ca&#x1e7;atay T, Fung HYJ, Li YC, Chook YM, Thomas PJ. Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. Sci Rep. 2018;8:7083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935693</ArticleId><ArticleId IdType="pubmed">29728608</ArticleId></ArticleIdList></Reference><Reference><Citation>Archbold HC, Jackson KL, Arora A, Weskamp K, Tank EMH, Li X, et al. TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci Rep. 2018;8:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5854632</ArticleId><ArticleId IdType="pubmed">29545601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, Funk C, Abou-Ajram C, Hutten S, Funk EBE, Kehlenbach RH, et al. Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1. Sci Rep. 2018;8:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935713</ArticleId><ArticleId IdType="pubmed">29728564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo PH, Doudeva LG, Wang YT, Shen CKJ, Yuan HS. Structural insights into TDP-43 in nucleic-acid binding and domain interactions. Nucleic Acids Res. 2009;37:1799&#x2013;1808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665213</ArticleId><ArticleId IdType="pubmed">19174564</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz T, Hock EM, Ernst P, Foglieni C, Jambeau M, Gilhespy LAB, et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat Commun. 2017;8:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5491494</ArticleId><ArticleId IdType="pubmed">28663553</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Kim HJ, Wang H, Monaghan J, Freyermuth F, Sung JC, et al. Nuclear-import receptors reverse aberrant phase transitions of rna-binding proteins with prion-like domains. Cell. 2018;173:677&#x2013;692.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Berning BA, Walker AK. The pathobiology of TDP-43 C-terminal fragments in ALS and FTLD. Front Neurosci. 2019;13:335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6470282</ArticleId><ArticleId IdType="pubmed">31031584</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji H, Arai T, Kametani F, Nonaka T, Yamashita M, Suzukake M, et al. Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain. 2012;135:3380&#x2013;3391.</Citation><ArticleIdList><ArticleId IdType="pubmed">23035040</ArticleId></ArticleIdList></Reference><Reference><Citation>Smethurst P, Sidle KCL, Hardy J. Review: prion-like mechanisms of transactive response DNA binding protein of 43&#x2009;kDa (TDP-43) in amyotrophic lateral sclerosis (ALS) Neuropathol Appl Neurobiol. 2015;41:578&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">25487060</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64:60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S, Sanelli T, Chiang H, Sun Y, Chakrabartty A, Keith J, et al. Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death. Acta Neuropathol. 2015;130:49&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468798</ArticleId><ArticleId IdType="pubmed">25788357</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Nonoka T, Kametani F, Yamashita M, Hosokawa M, et al. Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. Neuropathology. 2010;30:170&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">20102522</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon GS, Shim YM, Lee DY, Kim JS, Kang MJ, Ahn SH, et al. Pathological modification of TDP-43 in amyotrophic lateral sclerosis with SOD1 mutations. Mol Neurobiol. 2018;56:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6394608</ArticleId><ArticleId IdType="pubmed">29982983</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Yokoshi M, Okada H, Kawahara Y. The cleavage pattern of TDP-43 determines its rate of clearance and cytotoxicity. Nat Commun. 2015;6:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">25630387</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Xu YF, Dickey CA, Buratti E, Baralle F, Bailey R, et al. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci. 2007;27:10530&#x2013;10534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673167</ArticleId><ArticleId IdType="pubmed">17898224</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D, Capell A, Carlson AM, Shankaran SS, Rodde R, Neumann M, et al. Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. J Neurochem. 2009;110:1082&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">19522733</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel S, Herdewyn S, Fazal R, De Decker M, Moisse M, Robberecht W, et al. Progranulin reduces insoluble TDP-43 levels, slows down axonal degeneration and prolongs survival in mutant TDP-43 mice 11 medical and health sciences 1109 neurosciences. Mol Neurodegener. 2018;13:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6192075</ArticleId><ArticleId IdType="pubmed">30326935</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Brouwers N, Maurer-Stroh S, Van Es MA, Van Damme P, Van Vught PWJ, et al. Progranulin genetic variability contributes to amyotrophic lateral sclerosis. Neurology. 2008;71:253&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">18184915</ArticleId></ArticleIdList></Reference><Reference><Citation>Schymick JC, Yang Y, Andersen PM, Vonsattel JP, Greenway M, Momeni P, et al. Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. J Neurol Neurosurg Psychiatry. 2007;78:754&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117704</ArticleId><ArticleId IdType="pubmed">17371905</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin P, Guo X, Yang W, Yan S, Yang S, Zhao T, et al. Caspase-4 mediates cytoplasmic accumulation of TDP-43 in the primate brains. Acta Neuropathol. 2019;137:919&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6531422</ArticleId><ArticleId IdType="pubmed">30810811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004;36:40&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">14702039</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskowitz JH, Gozal YM, Duong DM, Dammer EB, Gearing M, Ye K, et al. Asparaginyl endopeptidase cleaves TDP-43 in brain. Proteomics. 2012;12:2455&#x2013;2463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3787696</ArticleId><ArticleId IdType="pubmed">22718532</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Hideyama T, Hachiga K, Teramoto S, Takano J, Iwata N, et al. A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat Commun. 2012;3:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">23250437</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao MV, Campbell J, Palaniappan A, Kumar A, Nixon RA. Calpastatin inhibits motor neuron death and increases survival of hSOD1 G93A mice. J Neurochem. 2016;137:253&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828294</ArticleId><ArticleId IdType="pubmed">26756888</ArticleId></ArticleIdList></Reference><Reference><Citation>Brower CS, Piatkov KI, Varshavsky A. Neurodegeneration-associated protein fragments as short-lived substrates of the N-end rule pathway. Mol Cell. 2013;50:161&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640747</ArticleId><ArticleId IdType="pubmed">23499006</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, Xu Y, et al. Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies. J Biol Chem. 2009;284:8516&#x2013;8524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659210</ArticleId><ArticleId IdType="pubmed">19164285</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H, Lee K, Matsuoka M. TDP-43-induced death is associated with altered regulation of BIM and Bcl-xL and attenuated by caspase-mediated TDP-43 cleavage. J Biol Chem. 2011;286:13171&#x2013;13183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3075664</ArticleId><ArticleId IdType="pubmed">21339291</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJY-J, Xu YFY-F, Cook C, Gendron TF, Roettges P, Link CD, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci. 2009;106:7607&#x2013;7612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Fan H, Ying Z, Li B, Wang H, Wang G. Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neurosci Lett. 2010;469:112&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">19944744</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, Tripathy K, Restrepo CR, Ge G, Xu Y, Kwong LK, et al. An insoluble frontotemporal lobar degeneration-associated TDP-43 C-terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice. Hum Mol Genet. 2015;24:7241&#x2013;7254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007600</ArticleId><ArticleId IdType="pubmed">26476406</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CC, Bose JK, Majumder P, Lee KH, Huang JTJ, Huang JK, et al. Metabolism and mis-metabolism of the neuropathological signature protein TDP-43. J Cell Sci. 2014;127:3024&#x2013;3038.</Citation><ArticleIdList><ArticleId IdType="pubmed">24860144</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G, Lomartire A, Mandili G, Lupino E, Buccinn&#xe0; B, Ramondetti C, et al. Reduced cellular Ca2+ availability enhances TDP-43 cleavage by apoptotic caspases. Biochim Biophys Acta. 2014;1843:725&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">24440855</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenoy J, El Mammeri N, Dutour A, Berbon M, Saad A, Lends A, et al. Structural dissection of amyloid aggregates of TDP-43 and its C-terminal fragments TDP-35 and TDP-16. FEBS J. 2019;287:2449&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">31782904</ArticleId></ArticleIdList></Reference><Reference><Citation>Osuru HP, Pramoonjago P, Abhyankar MM, Swanson E, Roker LTA, Cathro H, et al. Immunolocalization of TAR DNA-binding protein of 43 kDa (TDP-43) in mouse seminiferous epithelium. Mol Reprod Dev. 2017;84:675&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5577912</ArticleId><ArticleId IdType="pubmed">28600885</ArticleId></ArticleIdList></Reference><Reference><Citation>YAT K, Alemu S, Lamari A, Loew N, Brower CS. The N termini of TAR DNA-binding protein 43 (TDP43) C-Terminal fragments influence degradation, aggregation propensity, and morphology. Mol Cell Biol. 2018;38:e00243&#x2013;e00218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6146831</ArticleId><ArticleId IdType="pubmed">29987190</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Kametani F, Arai T, Akiyama H, Hasegawa M. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet. 2009;18:3353&#x2013;3364.</Citation><ArticleIdList><ArticleId IdType="pubmed">19515851</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno Y, Amari M, Takatama M, Aizawa H, Mihara B, Okamoto K. Immunoreactivities of p62, an ubiqutin-binding protein, in the spinal anterior horn cells of patients with amyotrophic lateral sclerosis. J Neurol Sci. 2006;249:13&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">16820172</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol. 2011;68:1440&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pubmed">22084127</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanji K, Zhang H-X, Mori F, Kakita A, Takahashi H, Wakabayashi K. p62/sequestosome 1 binds to TDP-43 in brains with frontotemporal lobar degeneration with TDP-43 inclusions. J Neurosci Res. 2012;90:2034&#x2013;2042.</Citation><ArticleIdList><ArticleId IdType="pubmed">22674379</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano T, Nakaso K, Nakashima K, Ohama E. Expression of ubiquitin-binding protein p62 in ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis with dementia: analysis of five autopsy cases with broad clinicopathological spectrum. Acta Neuropathol. 2004;107:359&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">14762676</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, Zennaro E, Fallini C, Weber M, Sommacal A, Buratti E, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009;111:1051&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderwyde T, Citro A, Mehta T, et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One. 2010;5:e13250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952586</ArticleId><ArticleId IdType="pubmed">20948999</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkening K, Leystra-Lantz C, Yang W, Jaffee H, Strong MJ. Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS) Brain Res. 2009;1305:168&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">19815002</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A, et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 2010;29:2841&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924641</ArticleId><ArticleId IdType="pubmed">20606625</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L, Lee VM, Trojanowksi JQ, Van Deerlin VM, Lee EB, Bonini NM. Poly-a binding Protein-1 localization to a subset of TDP-43 inclusions in amyotrophic lateral sclerosis occurs more frequently in patients harboring an expansion in C9orf72. J Neuropathol Exp Neurol. 2014;73:837&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4149258</ArticleId><ArticleId IdType="pubmed">25111021</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentmann E, Neumann M, Tahirovic S, Rodde R, Dormann D, Haass C. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43) J Biol Chem. 2012;287:23079&#x2013;23094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391091</ArticleId><ArticleId IdType="pubmed">22563080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Ivanov P. Stress granules and neurodegeneration. Nat Rev Neurosci. 2019;20:649&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6986315</ArticleId><ArticleId IdType="pubmed">31582840</ArticleId></ArticleIdList></Reference><Reference><Citation>Protter DSW, Parker R. Principles and properties of stress granules. Trends Cell Biol. 2016;26:668&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4993645</ArticleId><ArticleId IdType="pubmed">27289443</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, Alberti S, Fawzi NL, Mittag T, Polymenidou M, Rousseau F, et al. Protein phase separation: a new phase in cell biology. Trends Cell Biol. 2018;28:420&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6034118</ArticleId><ArticleId IdType="pubmed">29602697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha NL, Gupta M, Li W, Miller I, Anderson P. RNA-binding proteins TIA-1 and TIAR link the phosphorylation of eIF-2&#x3b1; to the assembly of mammalian stress granules. J Cell Biol. 1999;147:1431&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174242</ArticleId><ArticleId IdType="pubmed">10613902</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N, Cho MR, Li W, Yacono PW, Chen S, Gilks N, et al. Dynamic shuttling of TIA-1 accompanies the recruitment of mRNA to mammalian stress granules. J Cell Biol. 2000;151:1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190599</ArticleId><ArticleId IdType="pubmed">11121440</ArticleId></ArticleIdList></Reference><Reference><Citation>Tourri&#xe8;re H, Chebli K, Zekri L, Courselaud B, Blanchard JM, Bertrand E, et al. The RasGAP-associated endoribonuclease G3BP assembles stress granules. J Cell Biol. 2003;160:823&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173781</ArticleId><ArticleId IdType="pubmed">12642610</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuki H, Takahashi M, Higuchi M, Makokha GN, Oie M, Fujii M. Both G3BP1 and G3BP2 contribute to stress granule formation. Genes Cells. 2013;18:135&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">23279204</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Nicholson AM, Sarkar M, Messing J, Purice MD, Pottier C, et al. TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. Neuron. 2017;95:808&#x2013;816.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576574</ArticleId><ArticleId IdType="pubmed">28817800</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald KK, Aulas A, Destroismaisons L, Pickles S, Beleac E, Camu W, et al. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum Mol Genet. 2011;20:1400&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pubmed">21257637</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalfallah Y, Kuta R, Grasmuck C, Prat A, Durham HD, Vande Velde C. TDP-43 regulation of stress granule dynamics in neurodegenerative disease-relevant cell types. Sci Rep. 2018;8:7551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5953947</ArticleId><ArticleId IdType="pubmed">29765078</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewey CM, Cenik B, Sephton CF, Dries DR, Mayer P, Good SK, et al. TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. Mol Cell Biol. 2011;31:1098&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067820</ArticleId><ArticleId IdType="pubmed">21173160</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Cohen TJ. Aggregation of the nucleic acid&#x2013; binding protein TDP-43 occurs via distinct routes that are coordinated with stress granule formation. J Biol Chem. 2019;294:jbc.RA118.006351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416430</ArticleId><ArticleId IdType="pubmed">30630951</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Fan B, Yang P, Temirov J, Messing J, Kim HJ, et al. Chronic optogenetic induction of stress granules is cytotoxic and reveals the evolution of ALS-FTD pathology. Elife. 2019;8:e39578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426440</ArticleId><ArticleId IdType="pubmed">30893049</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Lu S, Yu H, Chen C, Melamed Z, Guo L, et al. Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death. Neuron. 2019;102:339&#x2013;357.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Babinchak WM, Haider R, Dumm BK, Sarkar P, Surewicz K, Choi JK, et al. The role of liquid-liquid phase separation in aggregation of the TDP-43 low-complexity domain. J Biol Chem. 2019;294:6306&#x2013;6317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6484124</ArticleId><ArticleId IdType="pubmed">30814253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, Gleixner AM, Mauna JC, Gomes E, DeChellis-Marks MR, Needham PG, et al. RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43. Neuron. 2019;102:321&#x2013;338.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L, Gomes E, Guo L, Mojsilovic-Petrovic J, Tran V, Kalb RG, et al. Poly(ADP-ribose) prevents pathological phase separation of TDP-43 by promoting liquid Demixing and stress granule localization. Mol Cell. 2018;71:703&#x2013;717.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6128762</ArticleId><ArticleId IdType="pubmed">30100264</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Vance C, Nishimura AL, Lee Y-BYB, Chen HJH-J, Urwin H, et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J Cell Sci. 2014;127:1263&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3953816</ArticleId><ArticleId IdType="pubmed">24424030</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477:211&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V, Renaud L, Bareil C, Julien JP. Neuronal expression of UBQLN2P497H exacerbates TDP-43 pathology in TDP-43G348C mice through interaction with ubiquitin. Mol Neurobiol. 2018;56:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6647471</ArticleId><ArticleId IdType="pubmed">30377984</ArticleId></ArticleIdList></Reference><Reference><Citation>Le NTT, Chang L, Kovlyagina I, Georgiou P, Safren N, Braunstein KE, et al. Motor neuron disease, TDP-43 pathology, and memory deficits in mice expressing ALS-FTD-linked UBQLN2 mutations. Proc Natl Acad Sci U S A. 2016;113:E7580&#x2013;E7589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127348</ArticleId><ArticleId IdType="pubmed">27834214</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Liu M, Huang C, Liu X, Huang B, Li N, et al. Pathogenic Ubqln2 gains toxic properties to induce neuron death. Acta Neuropathol. 2015;129:417&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4777328</ArticleId><ArticleId IdType="pubmed">25388785</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, Corcia P, Cazeneuve C, Boill&#xe9;e S, Seilhean D, Danel-Brunaud V, et al. Mutations in UBQLN2 are rare in French amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33:839.e1&#x2013;839.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">22169395</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doormaal PTC, van Rheenen W, van Blitterswijk M, Schellevis RD, Schelhaas HJ, de Visser M, et al. UBQLN2 in familial amyotrophic lateral sclerosis in the Netherlands. Neurobiol Aging. 2012;33:2233.e7&#x2013;2233.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22676852</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoud H, Suhail H, Szuto A, Camu W, Salachas F, Meininger V, et al. UBQLN2 mutations are rare in French and French-Canadian amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33:2230.e1&#x2013;2230.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">22560112</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eersel J, Ke YD, Gladbach A, Bi M, G&#xf6;tz J, Kril JJ, et al. Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. Iijima KM, editor. PLoS One. 2011;6:e22850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146516</ArticleId><ArticleId IdType="pubmed">21829535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Kawakami E, Endo K, Misawa H, Watabe K. Formation and spreading of TDP-43 aggregates in cultured neuronal and glial cells demonstrated by time-lapse imaging. PLoS One. 2017;12:e0179375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5466347</ArticleId><ArticleId IdType="pubmed">28599005</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson-Stone C, Hallupp M, Shahheydari H, Ragagnin AMG, Chatterton Z, Carew-Jones F, et al. CYLD is a causative gene for frontotemporal dementia-amyotrophic lateral sclerosis. Brain. 2020;143:783&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7089666</ArticleId><ArticleId IdType="pubmed">32185393</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, M&#xfc;ller K, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18:631&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>de Majo M, Topp SD, Smith BN, Nishimura AL, Chen HJ, Gkazi AS, et al. ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiol Aging. 2018;71:266.e1&#x2013;266.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6983933</ArticleId><ArticleId IdType="pubmed">30033073</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich M, Shepheard SR, Verber N, Wyles M, Heath PR, Highley JR, et al. Neuropathological characterization of a novel TANK binding kinase (TBK1) gene loss of function mutation associated with amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2019;46:279&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">31498468</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Meng P, Zheng Y, Mao Y, Hu F. Regulation of TDP-43 aggregation by phosphorylation andp62/SQSTM1. J Neurochem. 2011;116:248&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">21062285</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal J, Str&#xf6;m AL, Kilty R, Zhang F, Zhu H. p62 accumulates and enhances aggregate formation in model systems of familial amyotrophic lateral sclerosis. J Biol Chem. 2007;282:11068&#x2013;11077.</Citation><ArticleIdList><ArticleId IdType="pubmed">17296612</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW. Sequestosome 1/p62 is a Polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol. 2004;24:8055&#x2013;8068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC515032</ArticleId><ArticleId IdType="pubmed">15340068</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallini C, Bassell GJ, Rossoll W. The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth. Hum Mol Genet. 2012;21:3703&#x2013;3718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406762</ArticleId><ArticleId IdType="pubmed">22641816</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, Han SSW, et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014;81:536&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, Shaw CE, Traynor BJ, Landers Correspondence JE, et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron. 2018;97:1268&#x2013;1282.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Yilmaz R, M&#xfc;ller K, Grehl T, Petri S, Meyer T, et al. Hot-spot KIF5A mutations cause familial ALS. Brain. 2018;141:688&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837483</ArticleId><ArticleId IdType="pubmed">29342275</ArticleId></ArticleIdList></Reference><Reference><Citation>Puls I, Jonnakuty C, LaMonte BH, Holzbaur ELF, Tokito M, Mann E, et al. Mutant dynactin in motor neuron disease. Nat Genet. 2003;33:455&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">12627231</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;nch C, Sedlmeier R, Meyer T, Homberg V, Sperfeld AD, Kurt A, et al. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology. 2004;63:724&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">15326253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieran D, Hafezparast M, Bohnert S, Dick JRT, Martin J, Schiavo G, et al. A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J Cell Biol. 2005;169:561&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171702</ArticleId><ArticleId IdType="pubmed">15911875</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilsland LG, Sahai E, Kelly G, Golding M, Greensmith L, Schiavo G. Deficits in axonal transport precede ALS symptoms in vivo. Proc Natl Acad Sci U S A. 2010;107:20523&#x2013;20528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996651</ArticleId><ArticleId IdType="pubmed">21059924</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos KJ, Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? Neurobiol Dis. 2017;105:283&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536153</ArticleId><ArticleId IdType="pubmed">28235672</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh JN, Tosolini AP, Gordon D, Devoy A, Fratta P, Fisher EMC, et al. ALS mice carrying pathological mutant TDP-43, but not mutant FUS, display axonal transport defects in vivo. Cell Rep. 2020;31:3655&#x2013;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7090381</ArticleId><ArticleId IdType="pubmed">32187538</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, Siddegowda BB, Estes PS, Johannesmeyer J, Kovalik T, Daniel SG, et al. FUTSCH/MAP1B mRNA is a translational target of TDP-43 and is neuroprotective in a Drosophila model of amyotrophic lateral sclerosis. J Neurosci. 2014;34:15962&#x2013;15974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4244467</ArticleId><ArticleId IdType="pubmed">25429138</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder P, Chu JF, Chatterjee B, Swamy KBS, Shen CKJ. Co-regulation of mRNA translation by TDP-43 and fragile X syndrome protein FMRP. Acta Neuropathol. 2016;132:721&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5073124</ArticleId><ArticleId IdType="pubmed">27518042</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">15483602</ArticleId></ArticleIdList></Reference><Reference><Citation>Parone PA, Da Cruz S, Han JS, McAlonis-Downes M, Vetto AP, Lee SK, et al. Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. J Neurosci. 2013;33:4657&#x2013;4671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711648</ArticleId><ArticleId IdType="pubmed">23486940</ArticleId></ArticleIdList></Reference><Reference><Citation>Treusch S, Cyr DM, Lindquist S. Amyloid deposits: Protection against toxic protein species? Cell Cycle. 2009;8:1668&#x2013;1674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4451085</ArticleId><ArticleId IdType="pubmed">19411847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura A, Yuno S, Muto H, Kinjo M. Different aggregation states of a nuclear localization signal-tagged 25-kDa C-terminal fragment of TAR RNA/DNA-binding protein 43 kDa. Genes Cells. 2017;22:521&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">28497562</ArticleId></ArticleIdList></Reference><Reference><Citation>French RL, Grese ZR, Aligireddy H, Dhavale DD, Reeb AN, Kedia N, et al. Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation. J Biol Chem. 2019;294:6696&#x2013;6709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6497947</ArticleId><ArticleId IdType="pubmed">30824544</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang YS, Tsai KJ, Chang YJ, Kao P, Woods R, Kuo PH, et al. Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nat Commun. 2014;5:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">25215604</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Boyer DR, Sawaya MR, Ge P, Eisenberg DS. Cryo-EM structures of four polymorphic TDP-43 amyloid cores. Nat Struct Mol Biol. 2019;26:619&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7047951</ArticleId><ArticleId IdType="pubmed">31235914</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferri&#xe8;re F, Maniecka Z, P&#xe9;rez-Berlanga M, Hruska-Plochan M, Gilhespy L, Hock E-M, et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat Neurosci. 2019;22:65&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Robinson JL, Malunda JA, Xie SX, Clark CM, Kwong LK, et al. Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol. 2010;67:1238&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050578</ArticleId><ArticleId IdType="pubmed">20937952</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R, Yang G, Nonaka T, Arai T, Jia W, Cynader MS. Reducing TDP-43 aggregation does not prevent its cytotoxicity. Acta Neuropathol Commun. 2014;2:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893365</ArticleId><ArticleId IdType="pubmed">24252504</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci. 2010;30:639&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821110</ArticleId><ArticleId IdType="pubmed">20071528</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E, Unger T, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest. 2011;121:726&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026736</ArticleId><ArticleId IdType="pubmed">21206091</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, Spiller KJ, Ge G, Zheng A, Xu Y, Zhou M, et al. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 2015;130:643&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127391</ArticleId><ArticleId IdType="pubmed">26197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaguri H, Chew J, Xu YF, Gendron TF, Garrett A, Lee CW, et al. The extreme N-terminus of TDP-43 mediates the cytoplasmic aggregation of TDP-43 and associated toxicity in vivo. Brain Res. 2016;1647:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003772</ArticleId><ArticleId IdType="pubmed">27155453</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, Ling S-C, Huelga SC, Lagier-Tourenne C, Polymenidou M, Ditsworth D, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A. 2013;110:E736&#x2013;E745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Maniecka Z, Polymenidou M. From nucleation to widespread propagation: a prion-like concept for ALS. Virus Res. 2015;207:94&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">25656065</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S, Xu Y, Restrepo CR, Kwong LK, Zhang B, Brown HJ, et al. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat Commun. 2018;9:4220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F, Tada M, Kon T, Miki Y, Tanji K, Kurotaki H, et al. Phosphorylated TDP-43 aggregates in skeletal and cardiac muscle are a marker of myogenic degeneration in amyotrophic lateral sclerosis and various conditions. Acta Neuropathol Commun. 2019;7:165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6816170</ArticleId><ArticleId IdType="pubmed">31661037</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogler TO. Wheeler JR, Nguyen ED, Hughes MP, Britson KA, Lester E, et al. TDP-43 and RNA form amyloid-like myo-granules in regenerating muscle. Nature. 2018;563:508&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324568</ArticleId><ArticleId IdType="pubmed">30464263</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Powell SZ, Appel JW, Arumanayagam AS, Rivera AL, Appel SH. Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2018;6:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899326</ArticleId><ArticleId IdType="pubmed">29653597</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero EN, Mitra J, Wang H, Rangaswamy S, Hegde PM, Basu P, et al. Amyotrophic lateral sclerosis (ALS)-associated TDP-43 mutation Q331K prevents nuclear translocation of XRCC4-DNA ligase 4 complex and is linked to genome damage-mediated neuronal apoptosis. Hum Mol Genet. 2019;28(5):2459&#x2013;2476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6659010</ArticleId><ArticleId IdType="pubmed">31067307</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;65:509&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859834</ArticleId><ArticleId IdType="pubmed">23797033</ArticleId></ArticleIdList></Reference><Reference><Citation>Asakawa K, Handa H, Kawakami K. Optogenetic modulation of TDP-43 oligomerization accelerates ALS-related pathologies in the spinal motor neurons. Nat Commun. 2020;11:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035286</ArticleId><ArticleId IdType="pubmed">32081878</ArticleId></ArticleIdList></Reference><Reference><Citation>Modic M, Rot G, Grosch M, Lepko T, Shaposhnikov D, Cacchiarelli D, et al. Cross-regulation between TDP-43 and Paraspeckles promotes pluripotency-differentiation transition. SSRN Electron J. 2018;74:951&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6561722</ArticleId><ArticleId IdType="pubmed">31047794</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, L&#xf3;pez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22:180&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349:650&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci. 2008;13:867&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">17981595</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14:452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, D&#xf6;rk T, Zuccato E, Pagani F, Romano M, Baralle FE. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001;20:1774&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC145463</ArticleId><ArticleId IdType="pubmed">11285240</ArticleId></ArticleIdList></Reference><Reference><Citation>Rot G, Wang Z, Huppertz I, Modic M, Len&#x10d;e T, Hallegger M, et al. High-resolution RNA maps suggest common principles of splicing and polyadenylation regulation by TDP-43. Cell Rep. 2017;19:1056&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5437728</ArticleId><ArticleId IdType="pubmed">28467899</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. Nat Publ Group. 2011;14:459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu JF, Majumder P, Chatterjee B, Huang SL, Shen CKJ. TDP-43 Regulates Coupled Dendritic mRNA Transport-Translation Processes in Co-operation with FMRP and Staufen1. Cell Rep. 2019;29:3118&#x2013;3133.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">31801077</ArticleId></ArticleIdList></Reference><Reference><Citation>Amlie-Wolf A, Ryvkin P, Tong R, Dragomir I, Suh E, Xu Y, et al. Transcriptomic changes due to cytoplasmic TDP-43 expression reveal dysregulation of histone transcripts and nuclear chromatin. Buratti E, editor. PLoS One. 2015;10:e0141836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4624943</ArticleId><ArticleId IdType="pubmed">26510133</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu LS, Cheng WC, Chen CY, Wu MC, Wang YC, Tseng YH, et al. Transcriptomopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons. Acta Neuropathol Commun. 2019;7:50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6440020</ArticleId><ArticleId IdType="pubmed">30922385</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong YH, Ling JP, Lin SZ, Donde AN, Braunstein KE, Majounie E, et al. Tdp-43 cryptic exons are highly variable between cell types. Mol Neurodegener. 2017;12:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5289002</ArticleId><ArticleId IdType="pubmed">28153034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiguro A, Kimura N, Noma T, Shimo-Kon R, Ishihama A, Kon T. Molecular dissection of ALS-linked TDP-43: involvement of the Gly-rich domain in interaction with G-quadruplex mRNA. FEBS Lett. 2020. 10.1002/1873-3468.13800.</Citation><ArticleIdList><ArticleId IdType="pubmed">32337711</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiguro A, Kimura N, Watanabe Y, Watanabe S, Ishihama A. TDP-43 binds and transports G-quadruplex-containing mRNAs into neurites for local translation. Genes to Cells. 2016;21:466&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">26915990</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B, Liu C, Geng Y, Zhu G. Topology of a G-quadruplex DNA formed by C9orf72 hexanucleotide repeats associated with ALS and FTD. Sci Rep. 2015;5:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643247</ArticleId><ArticleId IdType="pubmed">26564809</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon EG, Lu L, Sharma A, Yamazaki T, Tang T, Shneider NA, et al. The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. Elife. 2016;5:e17820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5050020</ArticleId><ArticleId IdType="pubmed">27623008</ArticleId></ArticleIdList></Reference><Reference><Citation>Fay MM, Anderson PJ, Ivanov P. ALS/FTD-associated C9ORF72 repeat RNA promotes phase transitions in vitro and in cells. Cell Rep. 2017;21:3573&#x2013;3584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5741101</ArticleId><ArticleId IdType="pubmed">29262335</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores BN, Li X, Martinez J, Beg AA, Barmada SJ. An Intramolecular Salt Bridge Linking TDP43&#x2019;s RNA Recognition Motifs Dictates RNA Binding and TDP43-Dependent Neurodegeneration. Cell Rep. 2019;27:1133&#x2013;1150.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6499398</ArticleId><ArticleId IdType="pubmed">31018129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara R, Matsukawa K, Nagata Y, Kunugi H, Tsuji S, Chihara T, et al. RNA binding mediates neurotoxicity in the transgenic Drosophila model of TDP-43 proteinopathy. Hum Mol Genet. 2013;22:4474&#x2013;4484.</Citation><ArticleIdList><ArticleId IdType="pubmed">23804749</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigt A, Herholz D, Fiesel FC, Kaur K, M&#xfc;ller D, Karsten P, et al. TDP-43-mediated neuron loss in vivo requires RNA-binding activity. Feany MB, editor. PLoS One. 2010;5:e12247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923622</ArticleId><ArticleId IdType="pubmed">20806063</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H-J, Topp SD, Hui HS, Zacco E, Katarya M, McLoughlin C, et al. RRM adjacent TARDBP mutations disrupt RNA binding and enhance TDP-43 proteinopathy. Brain. 2019;142:3753&#x2013;3770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6885686</ArticleId><ArticleId IdType="pubmed">31605140</ArticleId></ArticleIdList></Reference><Reference><Citation>Maharana S, Wang J, Papadopoulos DK, Richter D, Pozniakovsky A, Poser I, et al. RNA buffers the phase separation behavior of prion-like RNA binding proteins. Science. 2018;360:918&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091854</ArticleId><ArticleId IdType="pubmed">29650702</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalmansingh AS, Urekar CJ, Reddi PP. TDP-43 is a transcriptional repressor: the testis-specific mouse acrv1 gene is a TDP-43 target in vivo. J Biol Chem. 2011;286:10970&#x2013;10982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064152</ArticleId><ArticleId IdType="pubmed">21252238</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenk BM, Hartmann H, Serdaroglu A, Schludi MH, Hornburg D, Meissner F, et al. TDP-43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons. EMBO J. 2016;35:2350&#x2013;2370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5090220</ArticleId><ArticleId IdType="pubmed">27621269</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox LE, Ferraiuolo L, Goodall EF, Heath PR, Higginbottom A, Mortiboys H, et al. Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS) PLoS One. 2010;5:e9872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844426</ArticleId><ArticleId IdType="pubmed">20352044</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi Y, Fukuda Y, Yoshimura J, Toyoda A, Kurppa K, Moritoyo H, et al. Erbb4 mutations that disrupt the neuregulin-erbb4 pathway cause amyotrophic lateral sclerosis type 19. Am J Hum Genet. 2013;93:900&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824132</ArticleId><ArticleId IdType="pubmed">24119685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BW, Jeong YE, Wong M, Martin LJ. DNA damage accumulates and responses are engaged in human ALS brain and spinal motor neurons and DNA repair is activatable in iPSC-derived motor neurons with SOD1 mutations. Acta Neuropathol Commun. 2020;8:1&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6995159</ArticleId><ArticleId IdType="pubmed">32005289</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra J, Guerrero EN, Hegde PM, Liachko NF, Wang H, Vasquez V, et al. Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc Natl Acad Sci. 2019;116:4696&#x2013;4705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410842</ArticleId><ArticleId IdType="pubmed">30770445</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaikh AY, Martin LJ. DNA base-excision repair enzyme apurinic/apyrimidinic endonuclease/redox factor-1 is increased and competent in the brain and spinal cord of individuals with amyotrophic lateral sclerosis. NeuroMolecular Med. 2002;2:47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Engelhardt JI, Henkel JS, Sikl&#xf3;s L, So&#xf3;s J, Goodman C, et al. Widespread increased expression of the DNA repair enzyme PARP in brain in ALS. Neurology. 2004;62:319&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">14745081</ArticleId></ArticleIdList></Reference><Reference><Citation>Olkowski ZL. Mutant AP endonuclease in patients with amyotrophic lateral sclerosis. Neuroreport. 1998;9:239&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">9507962</ArticleId></ArticleIdList></Reference><Reference><Citation>Higelin J, Catanese A, Semelink-Sedlacek LL, Oeztuerk S, Lutz AK, Bausinger J, et al. NEK1 loss-of-function mutation induces DNA damage accumulation in ALS patient-derived motoneurons. Stem Cell Res. 2018;30:150&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">29929116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawaguchi T, Rollins MG, Moinpour M, Morera AA, Ebmeier CC, Old WM, et al. Changes to the TDP-43 and FUS Interactomes induced by DNA damage. J Proteome Res. 2020;19:360&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6947635</ArticleId><ArticleId IdType="pubmed">31693373</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006;12:440&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899408</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Jin L, Wang I, Wei W, Ho P, Liu Y, et al. HDAC1 dysregulation induces aberrant cell cycle and DNA damage in progress of TDP-43 proteinopathies. EMBO Mol Med. 2020;12(6):e10622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7278561</ArticleId><ArticleId IdType="pubmed">32449313</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani M, Zhao B, Gentil BJ, Minotti S, Marques C, Keith J, et al. Dysregulation of chromatin remodelling complexes in amyotrophic lateral sclerosis. Hum Mol Genet. 2017;26:4142&#x2013;4152.</Citation><ArticleIdList><ArticleId IdType="pubmed">28973294</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, Russ J, Cali CP, Phan JM, Amlie-Wolf A, Lee Correspondence EB. Loss of nuclear TDP-43 is associated with Decondensation of LINE retrotransposons. Cell Rep. 2019;27:1409&#x2013;1421.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508629</ArticleId><ArticleId IdType="pubmed">31042469</ArticleId></ArticleIdList></Reference><Reference><Citation>Birsa N, Bentham MP, Fratta P. Cytoplasmic functions of TDP-43 and FUS and their role in ALS. Semin Cell Dev Biol. Academic Press. 2019;99:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">31132467</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibiger C, Deisel J, Aufschnaiter A, Ambros S, Tereshchenko M, Verheijen BM, et al. TDP-43 controls lysosomal pathways thereby determining its own clearance and cytotoxicity. Hum Mol Genet. 2018;27:1593&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pubmed">29474575</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Coyne AN, Pei F, Vaughan S, Chaung M, Zarnescu DC, et al. Endocytosis regulates TDP-43 toxicity and turnover. Nat Commun. 2017;8:2092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5727062</ArticleId><ArticleId IdType="pubmed">29233983</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Byrd A, Warner AN, Pei F, Basha E, Buchanan A, et al. Cdc48/VCP and Endocytosis Regulate TDP-43 and FUS Toxicity and Turnover. Mol Cell Biol. 2019;40:e00256&#x2013;e00219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6996276</ArticleId><ArticleId IdType="pubmed">31767634</ArticleId></ArticleIdList></Reference><Reference><Citation>Smethurst P, Risse E, Tyzack GE, Mitchell JS, Taha DM, Chen YR, et al. Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis. Brain. 2020;143:430&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7009461</ArticleId><ArticleId IdType="pubmed">32040555</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata H, Peixoto P, Konrad C, Palomo G, Bredvik K, Gerges M, et al. Mutant TDP-43 does not impair mitochondrial bioenergetics in vitro and in vivo. Mol Neurodegener. 2017;12:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5422931</ArticleId><ArticleId IdType="pubmed">28482850</ArticleId></ArticleIdList></Reference><Reference><Citation>Benajiba L, Le BI, Camuzat A, Lacoste M, Thomas-Anterion C, Couratier P, et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol. 2009;65:470&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">19350673</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghero G, Pugliatti M, Marrosu F, Marrosu MG, Murru MR, Floris G, et al. Genetic architecture of ALS in Sardinia. Neurobiol Aging. 2014;35:2882.e7&#x2013;2882.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252367</ArticleId><ArticleId IdType="pubmed">25123918</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, Salachas F, Cazeneuve C, Gordon P, Bricka B, Camuzat A, et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J Med Genet. 2010;47:554&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">20577002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ticozzi N, LeClerc AL, van Blitterswijk M, Keagle P, McKenna-Yasek DM, Sapp PC, et al. Mutational analysis of TARDBP in neurodegenerative diseases. Neurobiol Aging. 2011;32:2096&#x2013;2099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889148</ArticleId><ArticleId IdType="pubmed">20031275</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Blitterswijk M, Van Es MA, Hennekam EAM, Dooijes D, Van Rheenen W, Medic J, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21:3776&#x2013;3784.</Citation><ArticleIdList><ArticleId IdType="pubmed">22645277</ArticleId></ArticleIdList></Reference><Reference><Citation>Nozaki I, Arai M, Takahashi K, Hamaguchi T, Yoshikawa H, Muroishi T, et al. Familial ALS with G298S mutation in TARDBP: a comparison of CSF tau protein levels with those in sporadic ALS. Intern Med. 2010;49:1209&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">20558945</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, Van Deerlin VM, Kwong LK, Yuan W, Wood EMC, Yu CE, et al. A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro. FEBS Lett. 2008;582:2252&#x2013;2256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2478749</ArticleId><ArticleId IdType="pubmed">18505686</ArticleId></ArticleIdList></Reference><Reference><Citation>Conforti FL, Sproviero W, Simone IL, Mazzei R, Valentino P, Ungaro C, et al. TARDBP gene mutations in south Italian patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82:587&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">20959352</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrado L, Ratti A, Gellera C, Buratti E, Castellotti B, Carlomagno Y, et al. High frequency of TARDBP gene mutations in italian patients with amyotrophic lateral sclerosis. Hum Mutat. 2009;30:688&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">19224587</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Bo R, Ghezzi S, Corti S, Pandolfo M, Ranieri M, Santoro D, et al. TARDBP (TDP-43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations. Eur J Neurol. 2009;16:727&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">19236453</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Durnall JC, Thoeng AD, Warraich ST, Nicholson GA, Blair IP. A novel TARDBP mutation in an Australian amyotrophic lateral sclerosis kindred. J Neurol Neurosurg Psychiatry. 2009;80:1286&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">19864664</ArticleId></ArticleIdList></Reference><Reference><Citation>Pamphlett R, Luquin N, McLean C, Jew SK, Adams L. TDP-43 neuropathology is similar in sporadic amyotrophic lateral sclerosis with or without TDP-43 mutations. Neuropathol Appl Neurobiol. 2009;35:222&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">18986339</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa H, Yamashita T, Kato H, Kimura T, Kwak S. Impaired nucleoporins are present in sporadic amyotrophic lateral sclerosis motor neurons that exhibit mislocalization of the 43-kDa TAR DNA-binding protein. J Clin Neurol. 2019;15:62&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6325357</ArticleId><ArticleId IdType="pubmed">30618218</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou CC, Zhang YJY, Umoh ME, Vaughan SW, Lorenzini I, Liu F, et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci. 2018;21:228&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EGP, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ditsworth D, Maldonado M, McAlonis-Downes M, Sun S, Seelman A, Drenner K, et al. Mutant TDP-43 within motor neurons drives disease onset but not progression in amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133:907&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427168</ArticleId><ArticleId IdType="pubmed">28357566</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, Bogaert E, Michiels E, Gijselinck I, Sieben A, Jovi&#x10d;i&#x107; A, et al. Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Sci Rep. 2016;6:20877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4751451</ArticleId><ArticleId IdType="pubmed">26869068</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee KH, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovi&#x10d;i&#x10d; A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci. 2015;18:1226&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi KY, Mori E, Nizami ZF, Lin Y, Kato M, Xiang S, et al. Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proc Natl Acad Sci U S A. 2017;114:E1111&#x2013;E1117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5320981</ArticleId><ArticleId IdType="pubmed">28069952</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Ba&#xf1;ez-Coronel M, Reid T, Pletnikova O, Lewis J, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. 2013;110:E4968&#x2013;E4977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Arzberger T, Gr&#xe4;sser FA, Gijselinck I, May S, Rentzsch K, et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 2013;126:881&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon DA, Stepto A, Au WH, Adachi Y, Diaper DC, Hall R, et al. A feedback loop between dipeptide-repeat protein, TDP-43 and karyopherin-&#x3b1; mediates C9orf72-related neurodegeneration. Brain. 2018;141:2908&#x2013;2924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6158706</ArticleId><ArticleId IdType="pubmed">30239641</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. TDP-43 post-translational modifications in health and disease. Expert Opin Ther Targets. 2018;22(3):279&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">29431050</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, McMillan PJ, Guthrie CR, Bird TD, Leverenz JB, Kraemer BC. CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann Neurol. 2013;74:39&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3775949</ArticleId><ArticleId IdType="pubmed">23424178</ArticleId></ArticleIdList></Reference><Reference><Citation>Alquezar C, Salado IG, De La Encarnaci&#xf3;n A, P&#xe9;rez DI, Moreno F, Gil C, et al. Targeting TDP-43 phosphorylation by casein kinase-1&#x3b4; inhibitors: a novel strategy for the treatment of frontotemporal dementia. Mol Neurodegener. 2016;11:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4852436</ArticleId><ArticleId IdType="pubmed">27138926</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, Nonaka T, Suzuki T, Arai T, Dohmae N, Akiyama H, et al. Identification of casein kinase-1 phosphorylation sites on TDP-43. Biochem Biophys Res Commun. 2009;382:405&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">19285963</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Suzuki G, Tanaka Y, Kametani F, Hirai S, Okado H, et al. Phosphorylation of TAR DNA-binding protein of 43 kDa (TDP-43) by truncated casein kinase 1&#x3b4; triggers mislocalization and accumulation of TDP-43. J Biol Chem. 2016;291:5473&#x2013;5483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786690</ArticleId><ArticleId IdType="pubmed">26769969</ArticleId></ArticleIdList></Reference><Reference><Citation>Krach F, Batra R, Wheeler EC, Vu AQ, Wang R, Hutt K, et al. Transcriptome&#x2013;pathology correlation identifies interplay between TDP-43 and the expression of its kinase CK1E in sporadic ALS. Acta Neuropathol. 2018;136:405&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6215775</ArticleId><ArticleId IdType="pubmed">29881994</ArticleId></ArticleIdList></Reference><Reference><Citation>Choksi DK, Roy B, Chatterjee S, Yusuff T, Bakhoum MF, Sengupta U, et al. TDP-43 phosphorylation by casein kinase i&#x3b5; promotes oligomerization and enhances toxicity in vivo. Hum Mol Genet. 2014;23:1025&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pubmed">24105464</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, Guthrie CR, Kraemer BC. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci. 2010;30:16208&#x2013;16219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3075589</ArticleId><ArticleId IdType="pubmed">21123567</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, McMillan PJ, Strovas TJ, Loomis E, Greenup L, Murrell JR, et al. The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. PLoS Genet. 2014;10:e1004803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4256087</ArticleId><ArticleId IdType="pubmed">25473830</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor LM, McMillan PJ, Liachko NF, Strovas TJ, Ghetti B, Bird TD, et al. Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration. Mol Neurodegener. 2018;13:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802059</ArticleId><ArticleId IdType="pubmed">29409526</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Yeh PA, Chiu HC, Tang CY, Tu BP. Hyperphosphorylation as a defense mechanism to reduce TDP-43 aggregation. Ginsberg SD, editor. PLoS One. 2011;6:e23075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3151276</ArticleId><ArticleId IdType="pubmed">21850253</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Reeb AN, Lin B, Subramanian P, Fey EE, Knoverek CR, et al. Heat shock-induced phosphorylation of TAR DNA-binding protein 43 (TDP-43) by MAPK/ERK kinase regulates TDP-43 function. J Biol Chem. 2017;292:5089&#x2013;5100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5377819</ArticleId><ArticleId IdType="pubmed">28167528</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Tsuchiya K. Motor neuron disease group accompanied by inclusions of unidentified protein signaled by ubiquitin. Neuropathology. 2004;24:117&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">15139588</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Hwang AW, Unger T, Trojanowski JQ, Lee VMY. Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. EMBO J. 2012;31:1241&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297986</ArticleId><ArticleId IdType="pubmed">22193716</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Hwang AW, Restrepo CR, Yuan CX, Trojanowski JQ, Lee VMY. An acetylation switch controls TDP-43 function and aggregation propensity. Nat Commun. 2015;6:5845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407365</ArticleId><ArticleId IdType="pubmed">25556531</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto Y, Ito D, Yagi T, Nihei Y, Tsunodo Y, Suzuki N. Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43. J Biol Chem. 2010;285:608&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804209</ArticleId><ArticleId IdType="pubmed">19887443</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvatori I, Ferri A, Scaricamazza S, Giovannelli I, Serrano A, Rossi S, et al. Differential toxicity of TAR DNA-binding protein 43 isoforms depends on their submitochondrial localization in neuronal cells. J Neurochem. 2018;146:585&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">29779213</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung G, Shi J, Deng H, Hou J, Wang C, Hong A, et al. Cytoplasmic translocation, aggregation, and cleavage of TDP-43 by enteroviral proteases modulate viral pathogenesis. Cell Death Differ. 2015;22:2087&#x2013;2097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4816113</ArticleId><ArticleId IdType="pubmed">25976304</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Sivakumar P, Humphrey J, Lo K, Ricketts T, Oliveira H, et al. Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO J. 2018;37:e98684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983119</ArticleId><ArticleId IdType="pubmed">29764981</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp K, Tank EM, Miguez R, McBride JP, G&#xf3;mez NB, White M, et al. Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS. J Clin Invest. 2020;130:1139&#x2013;1155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269575</ArticleId><ArticleId IdType="pubmed">31714900</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyama T, Teramoto S, Hachiga K, Yamashita T, Kwak S. Co-occurrence of TDP-43 Mislocalization with reduced activity of an RNA editing enzyme, ADAR2, in aged mouse motor neurons. Kano MR, editor. PLoS One. 2012;7:e43469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3423340</ArticleId><ArticleId IdType="pubmed">22916266</ArticleId></ArticleIdList></Reference><Reference><Citation>De Giorgio F, Maduro C, EMC F, Acevedo-Arozena A. Transgenic and physiological mouse models give insights into different aspects of amyotrophic lateral sclerosis. Dis Model Mech. 2019;12(1):dmm037424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6361152</ArticleId><ArticleId IdType="pubmed">30626575</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CL, Dastidar SG, Ling SC, Malik B, Ashe T, Wadhwa M, et al. Senataxin mutations elicit motor neuron degeneration phenotypes and yield TDP-43 mislocalization in ALS4 mice and human patients. Acta Neuropathol. 2018;136:425&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6098723</ArticleId><ArticleId IdType="pubmed">29725819</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunseich C, Patankar A, Amaya J, Watts JA, Li D, Ramirez P, et al. Clinical and molecular aspects of Senataxin mutations in amyotrophic lateral sclerosis 4. Ann Neurol. 2020;87:547&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7818251</ArticleId><ArticleId IdType="pubmed">31957062</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4) Am J Hum Genet. 2004;74:1128&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182077</ArticleId><ArticleId IdType="pubmed">15106121</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SL, Wu LS, Lee M, Chang CW, Cheng WC, Fang YS, et al. A robust TDP-43 knock-in mouse model of ALS. Acta Neuropathol Commun. 2020;8:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6975031</ArticleId><ArticleId IdType="pubmed">31964415</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebstein SY, Yagudayeva I, Shneider NA. Mutant TDP-43 causes early-stage dose-dependent motor neuron degeneration in a TARDBP Knockin mouse model of ALS. Cell Rep. 2019;26:364&#x2013;373.e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">30625319</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JC, Constable R, So E, Vance C, Scotter E, Glover L, et al. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. Acta Neuropathol Commun. 2015;3:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4479086</ArticleId><ArticleId IdType="pubmed">26108367</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrot J, Imhof S, Wainger BJ. Modeling cell-autonomous motor neuron phenotypes in ALS using iPSCs. Neurobiol Dis. 2020;134:104680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7002167</ArticleId><ArticleId IdType="pubmed">31759135</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilican B, Serio A, Barmada SJ, Nishimura AL, Sullivan GJ, Carrasco M, et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A. 2012;109:5803&#x2013;5808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3326463</ArticleId><ArticleId IdType="pubmed">22451909</ArticleId></ArticleIdList></Reference><Reference><Citation>Serio A, Bilican B, Barmada SJ, Ando DM, Zhao C, Siller R, et al. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc Natl Acad Sci U S A. 2013;110:4697&#x2013;4702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607024</ArticleId><ArticleId IdType="pubmed">23401527</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Almeida S, Lu Y, Nishimura AL, Peng L, Sun D, et al. Downregulation of MicroRNA-9 in iPSC-derived neurons of FTD/ALS patients with TDP-43 mutations. Pandey U, editor. PLoS One. 2013;8:e76055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3797144</ArticleId><ArticleId IdType="pubmed">24143176</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank SA. Somatic evolutionary genomics: mutations during development cause highly variable genetic mosaicism with risk of cancer and neurodegeneration. Proc Natl Acad Sci U S A. 2010;107:1725&#x2013;1730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868288</ArticleId><ArticleId IdType="pubmed">19805033</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84:130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Gissl&#xe9;n M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the Neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference><Reference><Citation>Li QF, Dong Y, Yang L, Xie JJ, Ma Y, Du YC, et al. Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3. Mol Neurodegener. 2019;14:39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829913</ArticleId><ArticleId IdType="pubmed">31684998</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer&#x2019;s disease. Nat Med. 2019;25:277&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai L, Huang J. Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study. Neuropsychiatr Dis Treat. 2018;14:2241&#x2013;2254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6126505</ArticleId><ArticleId IdType="pubmed">30214214</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JM, McDade K, Livesey MR, Croy I, Marion de Proce S, Aitman T, et al. Spatial transcriptomics identifies spatially dysregulated expression of GRM3 and USP47 in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. Blackwell Publishing Ltd. 2020. 10.1111/nan.12597.</Citation><ArticleIdList><ArticleId IdType="pubmed">31925813</ArticleId></ArticleIdList></Reference><Reference><Citation>Maniatis S, &#xc4;ij&#xf6; T, Vickovic S, Braine C, Kang K, Mollbrink A, et al. Spatiotemporal dynamics of molecular pathology in amyotrophic lateral sclerosis. Science. 2019;364:89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">30948552</ArticleId></ArticleIdList></Reference><Reference><Citation>Otake K, Kamiguchi H, Hirozane Y. Identification of biomarkers for amyotrophic lateral sclerosis by comprehensive analysis of exosomal mRNAs in human cerebrospinal fluid. BMC Med Genomics. 2019;12:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6329125</ArticleId><ArticleId IdType="pubmed">30630471</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucca S, Gagliardi S, Pandini C, Diamanti L, Bordoni M, Sproviero D, et al. RNA-seq profiling in peripheral blood mononuclear cells of amyotrophic lateral sclerosis patients and controls. Sci Data. 2019;6:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6362931</ArticleId><ArticleId IdType="pubmed">30720798</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack GE, Luisier R, Taha DM, Neeves J, Modic M, Mitchell JS, et al. Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain. 2019;142(9):2572&#x2013;2580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6735815</ArticleId><ArticleId IdType="pubmed">31368485</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobingier BT, H&#xfc;ttenhain R, Eichel K, Miller KB, Ting AY, von Zastrow M, et al. An approach to spatiotemporally resolve protein interaction networks in living cells. Cell. 2017;169:350&#x2013;360.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5616215</ArticleId><ArticleId IdType="pubmed">28388416</ArticleId></ArticleIdList></Reference><Reference><Citation>Roux KJ, Kim DI, Burke B. BioID: A screen for protein-protein interactions. Curr Protoc Protein Sci. 2013;2013:19.23.1&#x2013;19.23.14.</Citation></Reference><Reference><Citation>Fazal FM, Han S, Parker KR, Kaewsapsak P, Xu J, Boettiger AN, et al. Atlas of subcellular RNA localization revealed by APEX-Seq. Cell. 2019;178:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786773</ArticleId><ArticleId IdType="pubmed">31230715</ArticleId></ArticleIdList></Reference><Reference><Citation>Padr&#xf3;n A, Iwasaki S, Ingolia NT. Proximity RNA Labeling by APEX-Seq Reveals the Organization of Translation Initiation Complexes and Repressive RNA Granules. Mol Cell. 2019;75:875&#x2013;887.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6834362</ArticleId><ArticleId IdType="pubmed">31442426</ArticleId></ArticleIdList></Reference><Reference><Citation>Markmiller S, Soltanieh S, Server KL, Bennett EJ, L&#xe9; E, Yeo Correspondence GW. Context-Dependent and Disease-Specific Diversity in Protein Interactions within Stress Granules. Cell. 2018;172:590&#x2013;598.e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5969999</ArticleId><ArticleId IdType="pubmed">29373831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ule J, Jensen KB, Ruggiu M, Mele A, Ule A, Darnell RB. CLIP Identifies Nova-Regulated RNA Networks in the brain. Science. 2003;302:1212&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pubmed">14615540</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol. 2008;67:1159&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">19018245</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007;114:221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">17653732</ArticleId></ArticleIdList></Reference><Reference><Citation>Chornenkyy Y, Fardo DW, Nelson PT. Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy. Lab Investig. 2019;99:993&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6609463</ArticleId><ArticleId IdType="pubmed">30742063</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Masuda-Suzukake M, Hosokawa M, Shimozawa A, Hirai S, Okado H, et al. C9ORF72 dipeptide repeat poly-GA inclusions promote intracellular aggregation of phosphorylated TDP-43. Hum Mol Genet. 2018;27:2658&#x2013;2670.</Citation><ArticleIdList><ArticleId IdType="pubmed">29750243</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>